The antitrust review of Thermo Fisher Scientific's proposed acquisition of genetic testing company Qiagen is likely to focus on the companies’ overlaps in sample preparation for next-generation sequencing, or NGS.Medical technology company Thermo Fisher announced on March 3 its plans to buy Netherlands-based holding company Qiagen for $11.5 billion. Qiagen makes genetic-testing